Login to Your Account



Stock Plunges

BioMS, Lilly Scratch Heads Over Dirucotide Phase III MS Blowup

By Jennifer Boggs


Wednesday, July 29, 2009
Shares of small Canadian biotech BioMS Medical Corp. took a beating after its only drug candidate, dirucotide, failed to delay disease progression over placebo in a Phase III trial in secondary progressive multiple sclerosis patients. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription